1
|
Nienstedt R, Schlagenhauff B, Rümmelein BC. [Treatment of therapy-resistant verruca plantaris with laser-assisted photodynamic therapy (PDT) with methyl aminolevulinate (MAL)]. DERMATOLOGIE (HEIDELBERG, GERMANY) 2024; 75:71-74. [PMID: 37707554 DOI: 10.1007/s00105-023-05224-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 08/11/2023] [Indexed: 09/15/2023]
Abstract
Mosaic warts are a type of verruca vulgaris that occur almost exclusively on the soles of the feet. They are particularly known for their treatment resistance and high recurrence rate. Laser-assisted drug delivery (LADD) photodynamic therapy (PDT) with methyl aminolevulinate (MAL) offers a low pain treatment option with hardly any side effects in therapy-resistant cases of verruca plantaris. Pretreatment with an ablative fractional laser is especially important to obtain penetration of MAL through the human papillomavirus (HPV)-infected skin layer.
Collapse
Affiliation(s)
- Robert Nienstedt
- Dermacenter AG, Bahnhofstr. 15, 6403, Küssnacht am Rigi, Schweiz.
| | | | - Bettina C Rümmelein
- Dr. Rümmelein AG - House of Skin and Laser Medicine, Bürglistr. 1, 8802, Zürich, Schweiz
| |
Collapse
|
2
|
Bar-Ilan E, Bar J, Baniel A, Slodownik D, Artzi O, Samuelov L, Sprecher E, Mashiah J. Intralesional human papillomavirus vaccine for the treatment of recalcitrant cutaneous warts. J Dermatol 2023; 50:1373-1380. [PMID: 37501372 DOI: 10.1111/1346-8138.16905] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2023] [Revised: 06/14/2023] [Accepted: 07/10/2023] [Indexed: 07/29/2023]
Abstract
Human papillomavirus (HPV) is ubiquitously distributed in the population worldwide and its most frequent clinical presentation is cutaneous warts. Despite various treatment options currently available, many patients experience persistent and refractory disease. We sought to evaluate the clinical effectiveness and safety profile of intralesional HPV 9-valent vaccine for the treatment of recalcitrant warts. A retrospective study was performed for all cases of cutaneous warts treated with intralesional 9-valent HPV vaccine between January 2017 and March 2021. Epidemiologic, clinical, and treatment data, including safety and effectiveness scores, were reviewed. Our cohort was composed of 20 patients: 13 adults and seven children. Twelve patients (60%) displayed a complete response whereas 8 patients (40%) showed a partial response. Older age was associated with a better response to treatment, while a history of laser therapy was associated with a worse prognosis. Adverse events were local, transient, and negligible. No systemic adverse effects were reported. Intralesional 9-valent HPV vaccine may be considered for the treatment of recalcitrant cutaneous warts. Controlled studies are required to confirm these results.
Collapse
Affiliation(s)
- Efrat Bar-Ilan
- Division of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
| | - Jonathan Bar
- Division of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
| | - Avital Baniel
- Division of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Dan Slodownik
- Division of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Ofir Artzi
- Division of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Liat Samuelov
- Division of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
- Pediatric Dermatology Clinic, Sourasky Medical Center, Dana-Dwek Children's Hospital, Tel Aviv, Israel
| | - Eli Sprecher
- Division of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
- Pediatric Dermatology Clinic, Sourasky Medical Center, Dana-Dwek Children's Hospital, Tel Aviv, Israel
| | - Jacob Mashiah
- Division of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
- Pediatric Dermatology Clinic, Sourasky Medical Center, Dana-Dwek Children's Hospital, Tel Aviv, Israel
| |
Collapse
|
3
|
Merio L, Chanal J, Jachiet M, Pourcher V, Arnault JP, Jouhet C, Milpied-Homsi B, Bourgault-Villada I, Aubin F, Caux F, Fouéré S, Vicaut E, Beylot-Barry M, Chosidow O. Human papilloma virus vaccine for palmoplantar warts: A retrospective study of 18 patients. J Eur Acad Dermatol Venereol 2023; 37:e223-e225. [PMID: 35972053 DOI: 10.1111/jdv.18523] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2022] [Accepted: 08/08/2022] [Indexed: 01/19/2023]
Affiliation(s)
- Léa Merio
- Department of Dermatology, AP-HP, University Hospital of Henri Mondor, Créteil, France
| | - Johan Chanal
- Department of Dermatology, AP-HP, University Hospital of Paris Centre, Paris, France
| | - Marie Jachiet
- Department of Dermatology, AP-HP, University Hospital of Saint-Louis, Paris, France
| | - Valérie Pourcher
- Department of Infectious Disease, AP-HP, Sorbonne University, University Hospital of Pitié-Salpêtrière, Paris, France
| | | | | | | | - Isabelle Bourgault-Villada
- Department of Dermatology and Clinical Immunology, AP-HP, University Hospital of Ambroise Paré, Boulogne, France
| | - Francois Aubin
- Department of Dermatology and Inserm 1098, University Regional Hospital of Besançon, Besançon, France
| | - Frédéric Caux
- Department of Dermatology, AP-HP, University Hospital of Avicenne, Bobigny, France
| | - Sébastien Fouéré
- Center for Genital Pathology and STIs and HPV platform, AP-HP, University Hospital of Saint-Louis, Paris, France
| | - Eric Vicaut
- Clinical Research Unit of Lariboisière-Saint-Louis, AP-HP, Paris, France
| | - Marie Beylot-Barry
- Department of Dermatology, University Hospital of Bordeaux, Bordeaux, France
| | - Olivier Chosidow
- Department of Dermatology, AP-HP, University Hospital of Henri Mondor, Créteil, France.,Infestious Diseases and Sexually Transmitted Infection Working Group
| | -
- Infestious Diseases and Sexually Transmitted Infection Working Group
| |
Collapse
|
4
|
Kost Y, Deutsch A, Zhu TH, Hulur I, Blasiak RC. Vaccination against human papillomavirus is not associated with resolution of verruca vulgaris in immunocompetent 9- to 21-year olds. J Am Acad Dermatol 2021; 87:250-252. [PMID: 34418514 DOI: 10.1016/j.jaad.2021.08.016] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2021] [Revised: 08/06/2021] [Accepted: 08/08/2021] [Indexed: 11/16/2022]
Affiliation(s)
- Yana Kost
- Department of Medicine, Division of Dermatology, Albert Einstein College of Medicine, Bronx, New York
| | - Alana Deutsch
- Department of Medicine, Division of Dermatology, Albert Einstein College of Medicine, Bronx, New York
| | - Tian Hao Zhu
- Department of Medicine, Division of Dermatology, Albert Einstein College of Medicine, Bronx, New York
| | - Imge Hulur
- Department of Medicine, Division of Dermatology, Albert Einstein College of Medicine, Bronx, New York
| | - Rachel C Blasiak
- Department of Medicine, Division of Dermatology, Albert Einstein College of Medicine, Bronx, New York; Division of Dermatology, Jacobi Medical Center, Bronx, New York.
| |
Collapse
|
5
|
Shin JO, Son JH, Lee J, Kim HS, Ko HC, Kim BS, Kim MB, Shin K. Nonavalent human papilloma virus vaccine for the treatment of multiple recalcitrant warts: An open-label study. J Am Acad Dermatol 2021; 86:940-941. [PMID: 33785384 DOI: 10.1016/j.jaad.2021.03.074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2021] [Revised: 03/19/2021] [Accepted: 03/24/2021] [Indexed: 10/21/2022]
Affiliation(s)
- Jun-Oh Shin
- Department of Dermatology, College of Medicine, Pusan National University, Busan, Korea; Department of Dermatology, Pusan National University Yangsan Hospital, Yangsan, Korea
| | - Jin-Hwa Son
- Department of Dermatology, College of Medicine, Pusan National University, Busan, Korea; Department of Dermatology, Pusan National University Yangsan Hospital, Yangsan, Korea
| | - Jungsoo Lee
- Department of Dermatology, College of Medicine, Pusan National University, Busan, Korea; Department of Dermatology, Pusan National University Yangsan Hospital, Yangsan, Korea
| | - Hoon-Soo Kim
- Department of Dermatology, College of Medicine, Pusan National University, Busan, Korea
| | - Hyun-Chang Ko
- Department of Dermatology, College of Medicine, Pusan National University, Busan, Korea; Department of Dermatology, Pusan National University Yangsan Hospital, Yangsan, Korea; Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Korea
| | - Byung-Soo Kim
- Department of Dermatology, College of Medicine, Pusan National University, Busan, Korea
| | - Moon-Bum Kim
- Department of Dermatology, College of Medicine, Pusan National University, Busan, Korea
| | - Kihyuk Shin
- Department of Dermatology, College of Medicine, Pusan National University, Busan, Korea; Department of Dermatology, Pusan National University Yangsan Hospital, Yangsan, Korea; Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Korea.
| |
Collapse
|
6
|
Mohta A, Kushwaha RK, Gautam U, Sharma P, Nyati A, Jain SK. A comparative study of the efficacy and safety of intralesional measles, mumps, and rubella vaccine versus intralesional vitamin D3 for the treatment of warts in children. Pediatr Dermatol 2020; 37:853-859. [PMID: 32681688 DOI: 10.1111/pde.14280] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
BACKGROUND Intralesional vitamin D3 has recently emerged as a new treatment for cutaneous warts. The use of the measles, mumps, and rubella (MMR) vaccine for this purpose is an established modality. However, relevant data on the efficacy of either the MMR vaccine or vitamin D3 as immunotherapy for cutaneous warts in the pediatric population are limited. OBJECTIVES To compare the efficacy and safety of intralesional injections of MMR vaccine to intralesional injections of vitamin D3 in children aged 8-16 years with multiple warts. METHODS A total of 74 children were randomly allocated into two groups. Group A patients received intralesional MMR vaccine into the largest wart, and group B received intralesional vitamin D3 into the largest wart. The injections were repeated every 4 weeks until clearance or for a maximum of three treatments. After the last injection, children were followed up every 2 weeks for 3 months, and at the sixth month, a final clinical assessment was conducted. RESULTS Of 74 children, 60 completed the study, with 30 children in each group. Complete clearance of the injected wart was observed in 26 (86.67%) patients in the MMR group (group A) and 23 (76.7%) patients in the vitamin D3 group (group B). Distant warts cleared in 23 (76.7%) patients in group A compared to 20 (66.6%) patients in group B. There was no significant difference between groups. No recurrence was seen in group A, whereas two (6.6%) children in group B exhibited recurrence in the ensuing 6-month follow-up. The most common adverse events were injection site pain and swelling. CONCLUSION Both intralesional MMR and vitamin D3 are safe, generally well-tolerated, and equally effective in children for the treatment of cutaneous warts.
Collapse
Affiliation(s)
- Alpana Mohta
- Department of Dermatology, Venereology and Leprosy, GMC, Kota, India
| | | | - Umesh Gautam
- Department of Dermatology, Venereology and Leprosy, GMC, Kota, India
| | - Pritee Sharma
- Department of Dermatology, Venereology and Leprosy, GMC, Kota, India
| | - Asha Nyati
- Department of Dermatology, Venereology and Leprosy, GMC, Kota, India
| | - Suresh Kumar Jain
- Department of Dermatology, Venereology and Leprosy, GMC, Kota, India
| |
Collapse
|